Detection of Dormant Chronic Myeloid Leukemia Clones in the Bone Marrow of Patients in Complete Molecular Remission

MRD is still detectable using clonogenic assays in some patients with CML after achieving CMR using TKI therapy, which is likely responsible for relapse on TKI discontinuation. Because of the large number of single colonies that need to be analyzed, the use of clonogenic assays in clinical practice to determine the feasibility of TKI discontinuation is not recommended.